Fundraising Fox
Scirhom
Martinsried, DE · Founded 2016 · 16 employees on LinkedIn · 4 known investors
Find your way into Scirhom
SciRhom is a biotech company developing first-in-class humanized antibodies against iRhom2, which regulates the enzyme TACE/ADAM17 to block pro-inflammatory signaling pathways. Its pipeline targets autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis.
Founders & leadership
Scirhom was founded in 2016 by Dr. Jens Ruhe and Dr. Matthias Schneider.
Investors · 4
How we know: the company's own site · a partner's Signal profile · Not right? Tell us
How we know: Hadean Ventures's portfolio page · the company's own site · Not right? Tell us
How we know: Kurma Partners's portfolio page · the company's own site · the VCSheet dataset · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AJul 2024 · 3 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
Frequently asked questions
- What does Scirhom do?
- SciRhom is a biotech company developing first-in-class humanized antibodies against iRhom2, which regulates the enzyme TACE/ADAM17 to block pro-inflammatory signaling pathways. Its pipeline targets autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis.
- Who founded Scirhom?
- Scirhom was founded by Dr. Jens Ruhe, Dr. Matthias Schneider in 2016.
- Who are Scirhom's investors?
- Scirhom's investors include Andera Partners, Hadean Ventures, Kurma Partners, Bayern Kapital.
- Where is Scirhom headquartered?
- Scirhom is headquartered in Martinsried, DE.